163 related articles for article (PubMed ID: 25274610)
1. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.
Yago MR; Frymoyer A; Benet LZ; Smelick GS; Frassetto LA; Ding X; Dean B; Salphati L; Budha N; Jin JY; Dresser MJ; Ware JA
AAPS J; 2014 Nov; 16(6):1358-65. PubMed ID: 25274610
[TBL] [Abstract][Full Text] [Related]
2. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.
Faber KP; Wu HF; Yago MR; Xu X; Kadiyala P; Frassetto LA; Benet LZ
Pharm Res; 2017 Mar; 34(3):619-628. PubMed ID: 28028768
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Pang J; Dalziel G; Dean B; Ware JA; Salphati L
Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
[TBL] [Abstract][Full Text] [Related]
4. Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.
Yago MR; Frymoyer AR; Smelick GS; Frassetto LA; Budha NR; Dresser MJ; Ware JA; Benet LZ
Mol Pharm; 2013 Nov; 10(11):4032-7. PubMed ID: 23980906
[TBL] [Abstract][Full Text] [Related]
5. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
[TBL] [Abstract][Full Text] [Related]
7. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
8. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
9. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Sun W; Klamerus KJ; Yuhas LM; Pawlak S; Plotka A; O'Gorman M; Kirkovsky L; Kosa M; Wang D
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):614-626. PubMed ID: 28430398
[TBL] [Abstract][Full Text] [Related]
10. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.
Musib L; Choo E; Deng Y; Eppler S; Rooney I; Chan IT; Dresser MJ
Mol Pharm; 2013 Nov; 10(11):4046-54. PubMed ID: 24010577
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
[TBL] [Abstract][Full Text] [Related]
13. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
14. Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles.
Murata M; Sugimoto M
Eur J Clin Pharmacol; 2020 Sep; 76(9):1253-1261. PubMed ID: 32488332
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults-cross-study comparison.
Thyssen A; Solanki B; Gonzalez M; Leitz G; Treem W; Mannaert E
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):406-16. PubMed ID: 27129014
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and disposition of dasatinib after oral administration to humans.
Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
[TBL] [Abstract][Full Text] [Related]
17. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Ochoa D; Román M; Cabaleiro T; Saiz-Rodríguez M; Mejía G; Abad-Santos F
BMC Pharmacol Toxicol; 2020 Jul; 21(1):54. PubMed ID: 32711578
[TBL] [Abstract][Full Text] [Related]
18. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.
Litou C; Vertzoni M; Goumas C; Vasdekis V; Xu W; Kesisoglou F; Reppas C
Pharm Res; 2016 Jun; 33(6):1399-412. PubMed ID: 26975361
[TBL] [Abstract][Full Text] [Related]
20. When Bioequivalence in Healthy Volunteers May not Translate to Bioequivalence in Patients: Differential Effects of Increased Gastric pH on the Pharmacokinetics of Levothyroxine Capsules and Tablets.
Seng Yue C; Benvenga S; Scarsi C; Loprete L; Ducharme MP
J Pharm Pharm Sci; 2015; 18(5):844-55. PubMed ID: 26670370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
